Consensus Target
High Target
Median Target
Low Target
| Date | Analyst | Company | Price Target | News Title |
|---|---|---|---|---|
| 2026-10-20 | N/A | Wells Fargo | $4.5 | TD Cowen Reiterates Hold Rating on Myriad Genetics (MYGN) |
| 2026-10-20 | N/A | Piper Sandler | $5 | Myriad Genetics upgraded to Neutral from Underweight at Piper Sandler |
| 2026-10-02 | N/A | Craig-Hallum | $8 | Myriad Genetics price target raised to $8 from $4 at Craig-Hallum |
| 2026-09-09 | N/A | UBS | $3.6 | Myriad Genetics assumed with a Neutral at UBS |
| 2026-09-01 | N/A | Piper Sandler | $2 | Myriad Genetics downgraded to Underweight from Overweight at Piper Sandler |
| 2026-08-18 | N/A | Stephens | $3 | Myriad Genetics price target lowered to $3 from $5 at Stephens |
| 2026-08-03 | N/A | Wells Fargo | $3 | Myriad Genetics price target lowered to $3 from $5.50 at Wells Fargo |
| 2026-02-24 | Lu Li | UBS | $6 | Myriad Genetics price target lowered to $6 from $8 at UBS |
| 2025-11-04 | Lu Li | UBS | $8 | Myriad Genetics price target raised to $8 from $6 at UBS |
| 2025-05-07 | Bill Bonello | Craig-Hallum | $18 | Myriad Genetics price target lowered to $18 from $29 at Craig-Hallum |